Medtronic touts Endurant stent graft data, lowered mortality

Medtronic (NYSE:MDT) today released data from the Engage global registry study of its Endurant abdominal aortic aneurysm stent graft, touting lowered mortality and rupture rates compared to the earlier Evar 1 trial. Data from the studies was presented at the 2016 Charing Cross Symposium in London, Fridley, Minn.-based Medtronic said. “In the comparison analysis of Engage and Evar 1 we can see just how far our medical advancements have come in improving patient outcomes with Evar. The very well-structured Evar 1 gave us the opportunity to understand the urgent need of improvement in Evar, especially in mid- and long-term endograft behavior. Thanks to large real world registries, such as Engage, we can do scrupulous analysis of different subgroups’ outcomes. The commitment from Medtronic to support a robust large scale registry is the type of clinical rigor that interventionalists have come to rely on and will propel us into the future in treating more challenging anatomies with minimally invasive options and long-term durability,” Engage investigator Dr. Dittmar Böckler of Germany’s University of Heidelberg said in a press release. The trial, which Medtronic said is the “most robust” post-market registry initiated in studying endovascular aortic repair, enrolled more than 1,200 patients at 79 sites and has follow-ups planned up to 10 years for patients enrolled. Data from the trial reported a 1.6% rate of aneurysm-related mortality in the...
Source: Mass Device - Category: Medical Equipment Authors: Tags: Clinical Trials Vascular Medtronic Source Type: news